Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVZO-1418 in Locally Advanced or Metastatic Solid Tumors
NCT07038343Phase 2Recruiting
- Sponsor
- Avenzo Therapeutics
- Start
- Jun 2025
- Primary completion
- Jun 2030
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of AVZO-1418 in solid tumor, lung cancer, biliary tract cancer (BTC) and 2 more (4 arms), sponsored by Avenzo Therapeutics. Primary endpoints: Dose Limiting Toxicities at 2 years, Maximum Tolerated Dose and Recommended Phase 2 Dose at 16 months and 2 more. Started Jun 2025; status: recruiting.
02
Drugs
AVZO-1418
03
Conditions
solid tumorlung cancerbiliary tract cancer (BTC)urothelial carcinoma (UC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07038343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07038343.